Rapid selection of sotrovimab escape variants in SARS-CoV-2 Omicron infected immunocompromised patients.
Smaranda GligaNadine LuebkeAlexander KillerHenning GruellAndreas WalkerAlexander T DiltheyCarolin LohrCharlotte FlaßhoveHans Martin OrthTorsten FeldtJohannes G BodeFlorian KleinJörg TimmTom LueddeBjörn-Erik Ole JensenPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
Immunocompromised patients face a considerable risk of prolonged viral shedding and emergence of escape mutations after early therapy with sotrovimab. These findings underscore the importance of careful monitoring and the need to conduct dedicated clinical trials for this patient population.